Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran
Various severe acute respiratory syndrome coronavirus 2 vaccines with different platforms have been administered worldwide; however, their effectiveness in critical cases of COVID‐19 has remained a concern. In this national cohort study, 24 016 intensive care unit (ICU) coronavirus disease‐2019 (COV...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2023-03, Vol.95 (3), p.e28607-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e28607 |
| container_title | Journal of medical virology |
| container_volume | 95 |
| creator | Jamaati, Hamidreza Karimi, Saeed Ghorbani, Fariba Panahi, Yunes Hosseini‐Baharanchi, Fatemeh Sadat Hajimoradi, Maryam Malek, Rayka Noorali, Sima Mokhtari, Majid Khoundabi, Batoul Sadr, Makan Mohamadnia, Abdolreza Zahraei, Seyed Mohsen Hashemian, Seyed MohammadReza Dastan, Farzaneh Mortaz, Esmaeil Tayeri, Katayoun Behtaj, Fatemeh Vaezi, Hassan Forouzanfar, Mohammad Mehdi Shafaghi, Shadi |
| description | Various severe acute respiratory syndrome coronavirus 2 vaccines with different platforms have been administered worldwide; however, their effectiveness in critical cases of COVID‐19 has remained a concern. In this national cohort study, 24 016 intensive care unit (ICU) coronavirus disease‐2019 (COVID‐19) admissions were included from January to April 2022. The mortality and length of ICU stay were compared between the vaccinated and unvaccinated patients. A total of 9428 (39.25%) patients were unvaccinated, and 14 588 (60.75%) patients had received at least one dose of the vaccine. Compared with the unvaccinated, the first, second, and third doses of vaccine resulted in 8%, 20%, and 33% lower risk of ICU mortality in the adjusted model, with risk ratio (RR): 0.92, 95% confidence interval (CI): 0.84–1.001, RR: 0.80, 95% CI: 0.77–0.83, and RR: 0.67, 95% CI: 0.64–0.71, respectively. The mean survival time was significantly shorter in the unvaccinated versus the fully vaccinated patients (hazard ratio [HR]: 0.84, 95% CI: 0.80–0.88); p |
| doi_str_mv | 10.1002/jmv.28607 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2779352323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2779352323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-542849b44db409a4a5fdeeda3a75f7d835eb77c0e77785514ccd865662d493723</originalsourceid><addsrcrecordid>eNp1kc9uEzEQhy0EoqFw4AWQJS7lsK3_rNdrblUoEFSUC-115dizjaNdb7C9QbnxCDwCrwKPwpPgTQoHJE4jjb75ZkY_hJ5Tck4JYRebfnfO6orIB2hGiaoKRSR9iGaEllVRVVScoCcxbgghtWLsMTrhVU2FIHKGfly1LZjkduAhRjy02LrcCeAT3mljnAe87XRqh9BH7DwOYMfcvcP9EJLuXNpj7S3uwN-l9TS_mN_gmPR-giPssuoAmOCSM7rDRkc4LJovbxdvfn39RtWEpjXgZe9MGPzP7zsdnM4XQNCv8SX2OrnBT7PDOm_N-tEe_Iug_VP0qNVdhGf39RTdvL36NH9fXC_fLeaX14XhgstClKwu1aos7aokSpdatBbAaq6laKWtuYCVlIaAlLIWgpbG2LoSVcVsqbhk_BSdHb3bMHweIaamd9FA12kPwxgbJqXignHGM_ryH3QzjCE_MFGKKlJzVWfq1ZHKP8cYoG22wfU67BtKminXJufaHHLN7It747jqwf4l_wSZgYsj8MV1sP-_qfnw8fao_A3r9a-J</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2791908398</pqid></control><display><type>article</type><title>Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Jamaati, Hamidreza ; Karimi, Saeed ; Ghorbani, Fariba ; Panahi, Yunes ; Hosseini‐Baharanchi, Fatemeh Sadat ; Hajimoradi, Maryam ; Malek, Rayka ; Noorali, Sima ; Mokhtari, Majid ; Khoundabi, Batoul ; Sadr, Makan ; Mohamadnia, Abdolreza ; Zahraei, Seyed Mohsen ; Hashemian, Seyed MohammadReza ; Dastan, Farzaneh ; Mortaz, Esmaeil ; Tayeri, Katayoun ; Behtaj, Fatemeh ; Vaezi, Hassan ; Forouzanfar, Mohammad Mehdi ; Shafaghi, Shadi</creator><creatorcontrib>Jamaati, Hamidreza ; Karimi, Saeed ; Ghorbani, Fariba ; Panahi, Yunes ; Hosseini‐Baharanchi, Fatemeh Sadat ; Hajimoradi, Maryam ; Malek, Rayka ; Noorali, Sima ; Mokhtari, Majid ; Khoundabi, Batoul ; Sadr, Makan ; Mohamadnia, Abdolreza ; Zahraei, Seyed Mohsen ; Hashemian, Seyed MohammadReza ; Dastan, Farzaneh ; Mortaz, Esmaeil ; Tayeri, Katayoun ; Behtaj, Fatemeh ; Vaezi, Hassan ; Forouzanfar, Mohammad Mehdi ; Shafaghi, Shadi</creatorcontrib><description>Various severe acute respiratory syndrome coronavirus 2 vaccines with different platforms have been administered worldwide; however, their effectiveness in critical cases of COVID‐19 has remained a concern. In this national cohort study, 24 016 intensive care unit (ICU) coronavirus disease‐2019 (COVID‐19) admissions were included from January to April 2022. The mortality and length of ICU stay were compared between the vaccinated and unvaccinated patients. A total of 9428 (39.25%) patients were unvaccinated, and 14 588 (60.75%) patients had received at least one dose of the vaccine. Compared with the unvaccinated, the first, second, and third doses of vaccine resulted in 8%, 20%, and 33% lower risk of ICU mortality in the adjusted model, with risk ratio (RR): 0.92, 95% confidence interval (CI): 0.84–1.001, RR: 0.80, 95% CI: 0.77–0.83, and RR: 0.67, 95% CI: 0.64–0.71, respectively. The mean survival time was significantly shorter in the unvaccinated versus the fully vaccinated patients (hazard ratio [HR]: 0.84, 95% CI: 0.80–0.88); p < 0.001). All vaccine platforms successfully decreased the hazard of ICU death compared with the unvaccinated group. The duration of ICU stay was significantly shorter in the fully vaccinated than in unvaccinated group (MD, −0.62, 95% CI: −0.82 to −0.42; p < 0.001). Since COVID‐19 vaccination in all doses and platforms has been able to reduce the risk of mortality and length of ICU‐stay, universal vaccination is recommended based on vaccine availability.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.28607</identifier><identifier>PMID: 36815507</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Cohort analysis ; Cohort Studies ; comorbidity ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Drug dosages ; Effectiveness ; Health hazards ; Humans ; ICU stay ; Immunization ; Intensive Care Units ; Iran - epidemiology ; Mortality ; Platforms ; Risk ; SARS-CoV-2 ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; vaccine ; Vaccines ; Viral diseases ; Virology</subject><ispartof>Journal of medical virology, 2023-03, Vol.95 (3), p.e28607-n/a</ispartof><rights>2023 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-542849b44db409a4a5fdeeda3a75f7d835eb77c0e77785514ccd865662d493723</citedby><cites>FETCH-LOGICAL-c3537-542849b44db409a4a5fdeeda3a75f7d835eb77c0e77785514ccd865662d493723</cites><orcidid>0000-0002-9960-8854</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.28607$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.28607$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36815507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jamaati, Hamidreza</creatorcontrib><creatorcontrib>Karimi, Saeed</creatorcontrib><creatorcontrib>Ghorbani, Fariba</creatorcontrib><creatorcontrib>Panahi, Yunes</creatorcontrib><creatorcontrib>Hosseini‐Baharanchi, Fatemeh Sadat</creatorcontrib><creatorcontrib>Hajimoradi, Maryam</creatorcontrib><creatorcontrib>Malek, Rayka</creatorcontrib><creatorcontrib>Noorali, Sima</creatorcontrib><creatorcontrib>Mokhtari, Majid</creatorcontrib><creatorcontrib>Khoundabi, Batoul</creatorcontrib><creatorcontrib>Sadr, Makan</creatorcontrib><creatorcontrib>Mohamadnia, Abdolreza</creatorcontrib><creatorcontrib>Zahraei, Seyed Mohsen</creatorcontrib><creatorcontrib>Hashemian, Seyed MohammadReza</creatorcontrib><creatorcontrib>Dastan, Farzaneh</creatorcontrib><creatorcontrib>Mortaz, Esmaeil</creatorcontrib><creatorcontrib>Tayeri, Katayoun</creatorcontrib><creatorcontrib>Behtaj, Fatemeh</creatorcontrib><creatorcontrib>Vaezi, Hassan</creatorcontrib><creatorcontrib>Forouzanfar, Mohammad Mehdi</creatorcontrib><creatorcontrib>Shafaghi, Shadi</creatorcontrib><title>Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>Various severe acute respiratory syndrome coronavirus 2 vaccines with different platforms have been administered worldwide; however, their effectiveness in critical cases of COVID‐19 has remained a concern. In this national cohort study, 24 016 intensive care unit (ICU) coronavirus disease‐2019 (COVID‐19) admissions were included from January to April 2022. The mortality and length of ICU stay were compared between the vaccinated and unvaccinated patients. A total of 9428 (39.25%) patients were unvaccinated, and 14 588 (60.75%) patients had received at least one dose of the vaccine. Compared with the unvaccinated, the first, second, and third doses of vaccine resulted in 8%, 20%, and 33% lower risk of ICU mortality in the adjusted model, with risk ratio (RR): 0.92, 95% confidence interval (CI): 0.84–1.001, RR: 0.80, 95% CI: 0.77–0.83, and RR: 0.67, 95% CI: 0.64–0.71, respectively. The mean survival time was significantly shorter in the unvaccinated versus the fully vaccinated patients (hazard ratio [HR]: 0.84, 95% CI: 0.80–0.88); p < 0.001). All vaccine platforms successfully decreased the hazard of ICU death compared with the unvaccinated group. The duration of ICU stay was significantly shorter in the fully vaccinated than in unvaccinated group (MD, −0.62, 95% CI: −0.82 to −0.42; p < 0.001). Since COVID‐19 vaccination in all doses and platforms has been able to reduce the risk of mortality and length of ICU‐stay, universal vaccination is recommended based on vaccine availability.</description><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>comorbidity</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Drug dosages</subject><subject>Effectiveness</subject><subject>Health hazards</subject><subject>Humans</subject><subject>ICU stay</subject><subject>Immunization</subject><subject>Intensive Care Units</subject><subject>Iran - epidemiology</subject><subject>Mortality</subject><subject>Platforms</subject><subject>Risk</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>vaccine</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>Virology</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9uEzEQhy0EoqFw4AWQJS7lsK3_rNdrblUoEFSUC-115dizjaNdb7C9QbnxCDwCrwKPwpPgTQoHJE4jjb75ZkY_hJ5Tck4JYRebfnfO6orIB2hGiaoKRSR9iGaEllVRVVScoCcxbgghtWLsMTrhVU2FIHKGfly1LZjkduAhRjy02LrcCeAT3mljnAe87XRqh9BH7DwOYMfcvcP9EJLuXNpj7S3uwN-l9TS_mN_gmPR-giPssuoAmOCSM7rDRkc4LJovbxdvfn39RtWEpjXgZe9MGPzP7zsdnM4XQNCv8SX2OrnBT7PDOm_N-tEe_Iug_VP0qNVdhGf39RTdvL36NH9fXC_fLeaX14XhgstClKwu1aos7aokSpdatBbAaq6laKWtuYCVlIaAlLIWgpbG2LoSVcVsqbhk_BSdHb3bMHweIaamd9FA12kPwxgbJqXignHGM_ryH3QzjCE_MFGKKlJzVWfq1ZHKP8cYoG22wfU67BtKminXJufaHHLN7It747jqwf4l_wSZgYsj8MV1sP-_qfnw8fao_A3r9a-J</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Jamaati, Hamidreza</creator><creator>Karimi, Saeed</creator><creator>Ghorbani, Fariba</creator><creator>Panahi, Yunes</creator><creator>Hosseini‐Baharanchi, Fatemeh Sadat</creator><creator>Hajimoradi, Maryam</creator><creator>Malek, Rayka</creator><creator>Noorali, Sima</creator><creator>Mokhtari, Majid</creator><creator>Khoundabi, Batoul</creator><creator>Sadr, Makan</creator><creator>Mohamadnia, Abdolreza</creator><creator>Zahraei, Seyed Mohsen</creator><creator>Hashemian, Seyed MohammadReza</creator><creator>Dastan, Farzaneh</creator><creator>Mortaz, Esmaeil</creator><creator>Tayeri, Katayoun</creator><creator>Behtaj, Fatemeh</creator><creator>Vaezi, Hassan</creator><creator>Forouzanfar, Mohammad Mehdi</creator><creator>Shafaghi, Shadi</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9960-8854</orcidid></search><sort><creationdate>202303</creationdate><title>Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran</title><author>Jamaati, Hamidreza ; Karimi, Saeed ; Ghorbani, Fariba ; Panahi, Yunes ; Hosseini‐Baharanchi, Fatemeh Sadat ; Hajimoradi, Maryam ; Malek, Rayka ; Noorali, Sima ; Mokhtari, Majid ; Khoundabi, Batoul ; Sadr, Makan ; Mohamadnia, Abdolreza ; Zahraei, Seyed Mohsen ; Hashemian, Seyed MohammadReza ; Dastan, Farzaneh ; Mortaz, Esmaeil ; Tayeri, Katayoun ; Behtaj, Fatemeh ; Vaezi, Hassan ; Forouzanfar, Mohammad Mehdi ; Shafaghi, Shadi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-542849b44db409a4a5fdeeda3a75f7d835eb77c0e77785514ccd865662d493723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>comorbidity</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Drug dosages</topic><topic>Effectiveness</topic><topic>Health hazards</topic><topic>Humans</topic><topic>ICU stay</topic><topic>Immunization</topic><topic>Intensive Care Units</topic><topic>Iran - epidemiology</topic><topic>Mortality</topic><topic>Platforms</topic><topic>Risk</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>vaccine</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jamaati, Hamidreza</creatorcontrib><creatorcontrib>Karimi, Saeed</creatorcontrib><creatorcontrib>Ghorbani, Fariba</creatorcontrib><creatorcontrib>Panahi, Yunes</creatorcontrib><creatorcontrib>Hosseini‐Baharanchi, Fatemeh Sadat</creatorcontrib><creatorcontrib>Hajimoradi, Maryam</creatorcontrib><creatorcontrib>Malek, Rayka</creatorcontrib><creatorcontrib>Noorali, Sima</creatorcontrib><creatorcontrib>Mokhtari, Majid</creatorcontrib><creatorcontrib>Khoundabi, Batoul</creatorcontrib><creatorcontrib>Sadr, Makan</creatorcontrib><creatorcontrib>Mohamadnia, Abdolreza</creatorcontrib><creatorcontrib>Zahraei, Seyed Mohsen</creatorcontrib><creatorcontrib>Hashemian, Seyed MohammadReza</creatorcontrib><creatorcontrib>Dastan, Farzaneh</creatorcontrib><creatorcontrib>Mortaz, Esmaeil</creatorcontrib><creatorcontrib>Tayeri, Katayoun</creatorcontrib><creatorcontrib>Behtaj, Fatemeh</creatorcontrib><creatorcontrib>Vaezi, Hassan</creatorcontrib><creatorcontrib>Forouzanfar, Mohammad Mehdi</creatorcontrib><creatorcontrib>Shafaghi, Shadi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jamaati, Hamidreza</au><au>Karimi, Saeed</au><au>Ghorbani, Fariba</au><au>Panahi, Yunes</au><au>Hosseini‐Baharanchi, Fatemeh Sadat</au><au>Hajimoradi, Maryam</au><au>Malek, Rayka</au><au>Noorali, Sima</au><au>Mokhtari, Majid</au><au>Khoundabi, Batoul</au><au>Sadr, Makan</au><au>Mohamadnia, Abdolreza</au><au>Zahraei, Seyed Mohsen</au><au>Hashemian, Seyed MohammadReza</au><au>Dastan, Farzaneh</au><au>Mortaz, Esmaeil</au><au>Tayeri, Katayoun</au><au>Behtaj, Fatemeh</au><au>Vaezi, Hassan</au><au>Forouzanfar, Mohammad Mehdi</au><au>Shafaghi, Shadi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2023-03</date><risdate>2023</risdate><volume>95</volume><issue>3</issue><spage>e28607</spage><epage>n/a</epage><pages>e28607-n/a</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>Various severe acute respiratory syndrome coronavirus 2 vaccines with different platforms have been administered worldwide; however, their effectiveness in critical cases of COVID‐19 has remained a concern. In this national cohort study, 24 016 intensive care unit (ICU) coronavirus disease‐2019 (COVID‐19) admissions were included from January to April 2022. The mortality and length of ICU stay were compared between the vaccinated and unvaccinated patients. A total of 9428 (39.25%) patients were unvaccinated, and 14 588 (60.75%) patients had received at least one dose of the vaccine. Compared with the unvaccinated, the first, second, and third doses of vaccine resulted in 8%, 20%, and 33% lower risk of ICU mortality in the adjusted model, with risk ratio (RR): 0.92, 95% confidence interval (CI): 0.84–1.001, RR: 0.80, 95% CI: 0.77–0.83, and RR: 0.67, 95% CI: 0.64–0.71, respectively. The mean survival time was significantly shorter in the unvaccinated versus the fully vaccinated patients (hazard ratio [HR]: 0.84, 95% CI: 0.80–0.88); p < 0.001). All vaccine platforms successfully decreased the hazard of ICU death compared with the unvaccinated group. The duration of ICU stay was significantly shorter in the fully vaccinated than in unvaccinated group (MD, −0.62, 95% CI: −0.82 to −0.42; p < 0.001). Since COVID‐19 vaccination in all doses and platforms has been able to reduce the risk of mortality and length of ICU‐stay, universal vaccination is recommended based on vaccine availability.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36815507</pmid><doi>10.1002/jmv.28607</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-9960-8854</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2023-03, Vol.95 (3), p.e28607-n/a |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2779352323 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Cohort analysis Cohort Studies comorbidity Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Drug dosages Effectiveness Health hazards Humans ICU stay Immunization Intensive Care Units Iran - epidemiology Mortality Platforms Risk SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 vaccine Vaccines Viral diseases Virology |
| title | Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A57%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20different%20vaccine%20platforms%20in%20reducing%20mortality%20and%20length%20of%20ICU%20stay%20in%20severe%20and%20critical%20cases%20of%20COVID%E2%80%9019%20in%20the%20Omicron%C2%A0variant%20era:%20A%20national%20cohort%20study%20in%20Iran&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Jamaati,%20Hamidreza&rft.date=2023-03&rft.volume=95&rft.issue=3&rft.spage=e28607&rft.epage=n/a&rft.pages=e28607-n/a&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.28607&rft_dat=%3Cproquest_cross%3E2779352323%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2791908398&rft_id=info:pmid/36815507&rfr_iscdi=true |